While standard operating procedures in Part 91 may be voluntary, adopting them is a critical step in professionalizing your ...

Investing.com - TD Cowen initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with a Buy rating on Wednesday, citing the potential of the company’s telitacicept therapy. The stock, currently trading ...

Vor Biopharma Inc. (NASDAQ:VOR) announced that its board of directors approved a repricing of certain outstanding stock options on Friday. The exercise price for eligible options was reduced to $8.18 ...

Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...

Upgrading to Windows 11 is still possible even after Windows 10 reached the end of support on October 14, 2025. Although many devices continue to run the retired operating system, switching to Windows ...

Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million. In ...

(RTTNews) - Vor Biopharma Inc. (VOR) announced the pricing of an underwritten public offering of 10 million shares of its common stock at a public offering price of $10.00 per share. The company ...

Lawyers at Lavoix provide an overview of the UPC’s approach to inventive step and whether the forum is promoting its own approach rather than following the EPO In patent litigation in Europe, validity ...

China’s far-reaching rules already affect manufacturers of semiconductors, cars and many other products. They will soon become much broader. By Keith Bradsher Reporting from Beijing Starting over a ...

Democratic backsliding, shifting geopolitics and competing priorities have made it harder for Europeans to promote human rights in the Middle East and North Africa. Yet the stability and prosperity of ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...